According to GlobalData, BIOFIRE RP2.1 is one of 108 product lines sold in the US covid-19 tests market; these product lines are sold by 60 different manufacturers. The average selling price for BIOFIRE RP2.1 decreased in hospitals, increased in health systems, and decreased outside of hospital facilities in 2022. The price of the BIOFIRE RP2.1 device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.
Smarter leaders trust GlobalData
The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.
In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as bioMerieux apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.
bioMerieux overview
bioMerieux SA (bioMerieux), a subsidiary of Institut Merieux SA, develops, manufactures, and markets in vitro diagnostic solutions for hospital and private laboratories. The company offers diagnostic solutions such as systems, reagents and software for the diagnosis of infectious diseases, cardiovascular diseases and cancers, besides identifying microorganisms in pharmaceuticals, cosmetics, and agri-food products. It offers immunoassays, microbiology products, molecular biology tests, and other solutions for clinical applications and industrial microbiological control solutions for the food, biopharmaceutical, and cosmetic industries; veterinary diagnostic laboratories; and blood banks. bioMerieux also provides solutions for the enumeration of bacterial flora, which indicate the quality of food products. The company distributes its products directly and through a network of distributors across the world. bioMerieux is headquartered in Marcy l’Etoile, France.
For a complete picture of BIOFIRE RP2.1, COVID-19 Tests pricing in the US, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
